Genentech has reported that the Phase III GOYA study evaluating Gazyva (obinutuzumab) and CHOP chemotherapy (G-CHOP) in patients with earlier untreated diffuse large B-cell lymphoma (DLBCL) did not meet its primary endpoint.

The primary endpoint is to significantly reduce the risk of disease worsening or death compared to Rituxan (rituximab) plus CHOP chemotherapy (R-CHOP).

Go deeper with GlobalData

Go deeper with GlobalData

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

The company reported that adverse events with Gazyva and Rituxan were consistent with those seen in earlier clinical trials when each was combined with several chemotherapies.

Genentech global product development head and chief medical officer Sandra Horning said: “Two previous studies showed Gazyva helped people with previously untreated follicular lymphoma or chronic lymphocytic leukemia live longer without their disease worsening compared to Rituxan, when each was combined with chemotherapy.

"We were hopeful we could show a similar result for people with diffuse large B-cell lymphoma and once again improve on the standard of care."

“We were hopeful we could show a similar result for people with diffuse large B-cell lymphoma and once again improve on the standard of care.”

Global Phase III open-label, multicentre, randomised, two-arm study GOYA (NCT01287741) examines the efficacy and safety of the combination of Gazyva along with CHOP chemotherapy (G-CHOP), compared to Rituxan and CHOP chemotherapy (R-CHOP).

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

The study included 1,418 previously untreated patients with CD20-positive DLBCL.

Gazyva is an engineered monoclonal antibody designed to attach to CD20, a protein found on certain types of B-cells.

It is believed to work by attacking targeted cells both directly and together with the body's immune system.

Gazyva was discovered by Roche Glycarta wholly owned, independent research unit of Roche.

Within the US, Gazyva is part of a collaboration between Roche Group member Genentech, and Biogen.

Clinical Trials Arena Excellence Awards - Nominations Closed

Nominations are now closed for the Clinical Trials Arena Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact.

Excellence in Action
Recognised with 2025 Excellence Awards for Research and Development and Marketing , Novotech converted FDA/EMA fast track designations into faster HDV trial timelines while translating complex HBV science into sponsor ready insights. Discover how this dual strength in execution and communication is reshaping liver disease clinical development.

Discover the Impact